Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - isoprenaline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - chloramphenicol -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil, quantity: 500 microgram/ml - injection, solution - excipient ingredients: ethanol - indications as at 14 january 1994: prostin vr sterile solution (alprostadil) is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival. such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of fallot, interruption of the aortic arch, coarctation of the aorta, mitral atresia, or transposition of the great vessels with or without other defects. prostin vr should be administered only by medically trained personnel in facilities in which paediatric patients can receive or have access to paediatric intensive care.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dantrolene sodium hemiheptahydrate, quantity: 50 mg - capsule - excipient ingredients: sodium lauryl sulfate; maize starch; lactose monohydrate; titanium dioxide; sunset yellow fcf; gelatin; iron oxide yellow; iron oxide red; magnesium stearate; purified talc; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - dantrium is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. there is no evidence that patients with contractures will benefit. dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy. if improvement occurs, it will ordinarily occur within the dosage titration schedule (see dosage and administration), as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrium. occasionally, subtle but meaningful improvements in spasticity may occur with dantrium therapy. in such instances informat

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dantrolene sodium hemiheptahydrate, quantity: 25 mg - capsule - excipient ingredients: titanium dioxide; sunset yellow fcf; purified talc; gelatin; iron oxide red; magnesium stearate; maize starch; sodium lauryl sulfate; lactose monohydrate; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - dantrium is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. there is no evidence that patients with contractures will benefit. dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy. if improvement occurs, it will ordinarily occur within the dosage titration schedule (see dosage and administration), as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without dantrium. occasionally, subtle but meaningful improvements in spasticity may occur with dantrium therapy. in such instances inf

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenylephrine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium metabisulfite; nitrogen; sodium chloride; citric acid - indications as at 01 jan 1991 : phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, of hypersensitivity. it is also employed to overcome paroxysmal supraventricular tachycardia, to prolong spinal anesthesia, and as a vasoconstrictor in regional analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - glipizide, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; stearic acid - minidiab is indicated as an adjunct to diet and exercise for the control of hyperglycaemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (niddm; type ii), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. in initiating treatment for non-insulin-dependent diabetes, diet should be emphasised as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycaemia. the importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment program fails to reduce symptoms and/or blood glucose the use of an oral sulphonylurea or insulin should be considered. use of minidiab must be viewed by both the physician and patient as a treatment in additio

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - potassium chloride -